MPOD (macular pigment optical density) devices measure a risk factor for AMD, not a physiological indicator of the disease. The AdaptDx Pro dark adaptometer measures a biomarker of the disease with 90% specificity and sensitivity. Impaired dark adaptation results from an AdaptDx Pro test signal that AMD is already present. Research has shown that there is no correlation between low MPOD levels and impaired dark adaptation.
Unlike MPOD devices, AdaptDx Pro testing is reimbursable under CPT code 92284 at a national average of $64.08.